ProPhase Labs is a company focused on diagnostic and genomic products and services, the development and commercialization of novel drugs, dietary supplements, and compounds, and contract manufacturing. Co. has identified two operating segments. The diagnostic services segment provides SARS-CoV-2 diagnostic information services to a range of customers in the U.S., including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the U.S. and also provides personal genomics products and services. We show 56 historical shares outstanding datapoints in our coverage of PRPH's shares outstanding history.
Understanding the changing numbers of PRPH shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like PRPH versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching PRPH by allowing them to research PRPH shares outstanding history
as well as any other stock in our coverage universe. |
Free PRPH Email Alerts:
Video: Shares Outstanding Importance
